Categories Earnings, Health Care

Dynavax Technologies Corporation (NASDAQ: DVAX): Q4 2019 Earnings Snapshot

— Biopharmaceutical company Dynavax Technologies Corporation (NASDAQ: DVAX) reported a net loss of $36.8 million $0.44 per share for the fourth quarter of 2019, vs. $0.33 per share loss expected.

— Total sales more than doubled year-over-year to $10.57 million, vs. $11.96 million expected

— Research and development expenses dropped to $12.3 million in the fourth quarter from $22.9 million last year

— Established research collaboration with the University of Queensland and the Coalition for Epidemic Preparedness to develop coronavirus vaccine

— Appointed Ryan Spencer chief executive officer and to the board of directors; named David Novack president and chief operating officer

— Expects HEPLISAV-B net product revenue to increase to $55-$62 million in fiscal 2020

— On track to release interim data from ongoing study of HEPLISAV-B in hemodialysis patients in the first quarter

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

What to expect when eBay (EBAY) reports Q4 2023 earnings

Shares of eBay Inc. (NASDAQ: EBAY) stayed red on Tuesday. The stock has gained 9% over the past three months. The ecommerce company is scheduled to report its earnings results

Earnings: Walmart (WMT) Q4 results beat estimates; revenues up 5.7%

Retail giant Walmart Inc. (NYSE: WMT) on Tuesday reported higher adjusted earnings and revenue for the fourth quarter of 2024. The numbers also came in above the consensus estimates. Fourth-quarter

Home Depot (HD) Q4 2023 Earnings: Key financials and quarterly highlights

Home Depot (NYSE: HD) reported fourth quarter 2023 earnings results today. Sales were $34.8 billion, down 2.9% from the same quarter a year ago. Comparable sales decreased 3.5%.  Net earnings were $2.8

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top